N@N

Ami Fadia Reiterated (BPMC) at Strong Buy and Held Target at $65 on, Aug 2nd, 2023

Ami Fadia of Needham, Reiterated "Blueprint Medicines Corporation" (BPMC) at Strong Buy and Held Target at $65 on, Aug 2nd, 2023.

Ami has made no other calls on BPMC in the last 4 months.

There are 8 other peers that have a rating on BPMC. Out of the 8 peers that are also analyzing BPMC, 2 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Michael Ulz of "Morgan Stanley" Reiterated at Hold and Held Target at $55 on, Friday, July 14th, 2023
• Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $46 on, Tuesday, May 23rd, 2023

These are the ratings of the 6 analyists that currently disagree with Ami

---

• Derek Archila of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $83 on, Monday, July 31st, 2023
• Andrew Berens of "SVB Leerink" Downgraded from Hold to Sell and Decreased Target to $43 on, Monday, June 5th, 2023
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $85 on, Tuesday, May 23rd, 2023
• Liana Moussatos of "Wedbush" Reiterated at Buy and Held Target at $75 on, Tuesday, May 23rd, 2023
• Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $82 on, Tuesday, May 23rd, 2023
• Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Tuesday, May 23rd, 2023

Contributing Sources

---